Tadalafil Tablet, Film Coated
Product Images NDC 71335-1884

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1884). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351884)

Label for Tadalafil 5mg tablet, film-coated, packaged by Bryant Ranch Prepack, Burbank, CA. The label compares this product to Cialis 5mg tablet by Sun Pharmaceutical Industries Ltd. It includes storage instructions to keep at room temperature (20-25°C) and a warning to keep drugs out of reach of children. The package count is 30 tablets with NDC 71335-1884-41.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

Four line graphs displaying the difference in systolic and diastolic blood pressure over time between Tadalafil and placebo. The graphs show changes in standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, measured over 0 to 96 hours. Each graph indicates the mean difference with error bars.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

A two-part line graph showing changes in systolic blood pressure over 24 hours post-dose. The top graph displays standing systolic blood pressure in mmHg, and the bottom graph shows supine systolic blood pressure in mmHg. Both graphs compare Tadalafil 20 mg with doxazosin 8 mg (solid line) versus placebo with doxazosin 8 mg (dotted line). The x-axis indicates time in hours post-dose.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin at 08:00. The graph compares four groups: tadalafil at 08:00, placebo at 08:00, tadalafil at 20:00, and placebo at 20:00, each with doxazosin given at 08:00. The y-axis measures systolic BP changes, and the x-axis represents time after administration in hours.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

A line chart showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing scenarios: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph includes error bars indicating variability at each time point.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg tablets to placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in score. The graph depicts a greater reduction in score for Tadalafil 5 mg compared to placebo across the treatment period.*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment period between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12) and the y-axis represents change in score. Data points show a greater reduction in IPSS scores for Tadalafil 5 mg compared to placebo, with statistical significance indicated at weeks 4 and 12 (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

A line graph depicting change from baseline in IPSS Total Score over 12 weeks of treatment. It compares Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles). The graph shows a greater decrease in scores with Tadalafil 5 mg across the treatment duration, with statistical significance noted at 12 weeks (p<0.01).*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

Chemical structure of Tadalafil, showing its fused ring system with nitrogen and oxygen atoms, including a methyl group and a methylenedioxyphenyl substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.